Rockefeller Capital Management’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Rockefeller Capital Management’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.9K	Sell	1,034 -22	-2%	-$1.21K	﹤0.01%	3205
2026 Q1	$55.3K	Sell	1,056 -59	-5%	-$3K	﹤0.01%	3224
2025 Q4	$57.1K	Buy	1,115 +20	+2%	+$925	﹤0.01%	3010
2025 Q3	$42.6K	Buy	+1,095	New	+$37.6K	﹤0.01%	2990
2023 Q1	–	Sell	-52	Closed	-$1K	–	3552
2022 Q4	$1K	Hold	52	–	–	﹤0.01%	3747
2022 Q3	$1K	Buy	52 +2	+4%	+$63	﹤0.01%	3778
2022 Q2	$1K	Hold	50	–	–	﹤0.01%	4007
2022 Q1	$1K	Hold	50	–	–	﹤0.01%	3772
2021 Q4	$2K	Hold	50	–	–	﹤0.01%	3565
2021 Q3	$2K	Buy	+50	New	+$2.29K	﹤0.01%	3477
2021 Q2	–	Sell	-4,000	Closed	-$201K	–	3580
2021 Q1	$201K	Hold	4,000	–	–	﹤0.01%	1330
2020 Q4	$204K	Hold	4,000	–	–	﹤0.01%	1186
2020 Q3	$164K	Hold	4,000	–	–	﹤0.01%	1106
2020 Q2	$167K	Hold	4,000	–	–	﹤0.01%	1007
2020 Q1	$127K	Buy	+4,000	New	+$153K	﹤0.01%	946

Other funds holding SBIO

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

CIS

Connors Investor Services Wyomissing, Pennsylvania $1.16B AUM 27.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MWM

Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Rockefeller Capital Management's SBIO Position: Q2 2026 in Review

Rockefeller Capital Management reduced its ALPS Medical Breakthroughs ETF (SBIO) stake by 2.1% in Q2 2026, selling an estimated $1.21K and leaving 1,034 shares worth $66.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3205.

Rockefeller Capital Management first reported a position in SBIO in Q1 2020 and has held it in 15 quarters since. The position peaked at $204K in Q4 2020. 66 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

Rockefeller Capital Management held 1,034 shares of ALPS Medical Breakthroughs ETF worth $66.9K as of Q2 2026.
Rockefeller Capital Management sold 22 ALPS Medical Breakthroughs ETF shares in Q2 2026, an estimated $1.21K.
ALPS Medical Breakthroughs ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3205 holding.
Rockefeller Capital Management first reported a position in ALPS Medical Breakthroughs ETF in Q1 2020 and has held it in 15 quarters since.
Rockefeller Capital Management's ALPS Medical Breakthroughs ETF position peaked at $204K in Q4 2020.
66 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.